FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381432829> ?p ?o ?g. }

• W4381432829 endingPage "100829" @default.
• W4381432829 startingPage "100829" @default.
• W4381432829 abstract "BackgroundPeople over 60 have been found to develop less protection after two doses of inactivated COVID-19 vaccines than younger people. Heterologous immunisation could potentially induce more robust immune responses compared to homologous immunisation. We aimed to assess the immunogenicity and safety of a heterologous immunisation with an adenovirus type 5-vectored vaccine (Ad5-nCOV, Convidecia) among elderly who were primed with an inactivated vaccine (CoronaVac) previously.MethodsWe did a randomised, observer-blinded, non-inferiority trial in healthy adults aged 60 years and older in Lianshui County (Jiangsu, China) between August 26, 2021 and May 15, 2022. 199 eligible participants who had received two doses of CoronaVac in the past 3–6 months were randomised (1:1) to receive a third dose of Convidecia (group A, n = 99) or CoronaVac (group B, n = 100), while 100 participants primed with one dose of CoronaVac in the past 1–2 months were randomised equally to receive a second dose of Convidecia (group C, n = 50) or CoronaVac (group D, n = 50). Participants and investigators were masked to the vaccine received. Primary outcomes were the geometric mean titers (GMTs) of neutralising antibodies against live SARS-CoV-2 virus 14 days after boosting and 28-day adverse reactions. This study was registered with ClinicalTrials.gov NCT04952727.FindingsA heterologous third dose of Convidecia resulted in a 6.2-fold (GMTs: 286.4 vs 48.2), 6.3-fold (45.9 vs 7.3) and 7.5-fold (32.9 vs 4.4) increase in neutralising antibodies against SARS-CoV-2 wild-type, delta (B.1.617.2) and omicron (BA.1.1) 14 days post boosting, respectively, compared with the homologous boost. The heterologous booster with Convidecia induced significantly higher neutralsing activities, with up to 91% inhibition in binding of Spike to ACE2 for BA.4 and BA.5 variants, compared with 35% inhibition induced by three doses of CoronaVac. For participants primed with one dose of CoronaVac, a heterologous dose of Convidecia induced higher neutralising antibodies against wild-type than two doses of CoronaVac (GMTs: 70.9 vs 9.3, p < 0.0001), but not for that against variants of concern (GMTs against delta: 5.0 vs 4.0, p = 0.4876; GMTs against omicron: 4.8 vs 3.7, p = 0.4707). Adverse reactions were reported by 8 (8.1%) participants in group A and 4 (4.0%) in group B (p ＞ 0.05), and 8 (16.0%) in group C and 1 (2.0%) in group D (p = 0.031).InterpretationIn elderly individuals primed with two doses of CoronaVac, the heterologous immunisation with Convidecia induced strong antibodies against SARS-CoV-2 wildtype and variants of concern, which could be an alternative regimen for enhancing protection in this vulnerable population.FundingNational Natural Science Foundation of China, Jiangsu Provincial Key Research and Development Program, and Jiangsu Science Fund for Distinguished Young Scholars Program. People over 60 have been found to develop less protection after two doses of inactivated COVID-19 vaccines than younger people. Heterologous immunisation could potentially induce more robust immune responses compared to homologous immunisation. We aimed to assess the immunogenicity and safety of a heterologous immunisation with an adenovirus type 5-vectored vaccine (Ad5-nCOV, Convidecia) among elderly who were primed with an inactivated vaccine (CoronaVac) previously. We did a randomised, observer-blinded, non-inferiority trial in healthy adults aged 60 years and older in Lianshui County (Jiangsu, China) between August 26, 2021 and May 15, 2022. 199 eligible participants who had received two doses of CoronaVac in the past 3–6 months were randomised (1:1) to receive a third dose of Convidecia (group A, n = 99) or CoronaVac (group B, n = 100), while 100 participants primed with one dose of CoronaVac in the past 1–2 months were randomised equally to receive a second dose of Convidecia (group C, n = 50) or CoronaVac (group D, n = 50). Participants and investigators were masked to the vaccine received. Primary outcomes were the geometric mean titers (GMTs) of neutralising antibodies against live SARS-CoV-2 virus 14 days after boosting and 28-day adverse reactions. This study was registered with ClinicalTrials.gov NCT04952727. A heterologous third dose of Convidecia resulted in a 6.2-fold (GMTs: 286.4 vs 48.2), 6.3-fold (45.9 vs 7.3) and 7.5-fold (32.9 vs 4.4) increase in neutralising antibodies against SARS-CoV-2 wild-type, delta (B.1.617.2) and omicron (BA.1.1) 14 days post boosting, respectively, compared with the homologous boost. The heterologous booster with Convidecia induced significantly higher neutralsing activities, with up to 91% inhibition in binding of Spike to ACE2 for BA.4 and BA.5 variants, compared with 35% inhibition induced by three doses of CoronaVac. For participants primed with one dose of CoronaVac, a heterologous dose of Convidecia induced higher neutralising antibodies against wild-type than two doses of CoronaVac (GMTs: 70.9 vs 9.3, p < 0.0001), but not for that against variants of concern (GMTs against delta: 5.0 vs 4.0, p = 0.4876; GMTs against omicron: 4.8 vs 3.7, p = 0.4707). Adverse reactions were reported by 8 (8.1%) participants in group A and 4 (4.0%) in group B (p ＞ 0.05), and 8 (16.0%) in group C and 1 (2.0%) in group D (p = 0.031). In elderly individuals primed with two doses of CoronaVac, the heterologous immunisation with Convidecia induced strong antibodies against SARS-CoV-2 wildtype and variants of concern, which could be an alternative regimen for enhancing protection in this vulnerable population." @default.
• W4381432829 created "2023-06-21" @default.
• W4381432829 creator A5003217623 @default.
• W4381432829 creator A5010401056 @default.
• W4381432829 creator A5011028975 @default.
• W4381432829 creator A5017618823 @default.
• W4381432829 creator A5028939852 @default.
• W4381432829 creator A5030821637 @default.
• W4381432829 creator A5038863647 @default.
• W4381432829 creator A5040179741 @default.
• W4381432829 creator A5049507373 @default.
• W4381432829 creator A5057822709 @default.
• W4381432829 creator A5058131596 @default.
• W4381432829 creator A5060962650 @default.
• W4381432829 creator A5063228983 @default.
• W4381432829 creator A5063333893 @default.
• W4381432829 creator A5065172118 @default.
• W4381432829 creator A5070046055 @default.
• W4381432829 creator A5070493054 @default.
• W4381432829 creator A5072289684 @default.
• W4381432829 creator A5077191016 @default.
• W4381432829 creator A5077645027 @default.
• W4381432829 creator A5083040893 @default.
• W4381432829 creator A5089746659 @default.
• W4381432829 creator A5090384196 @default.
• W4381432829 date "2023-06-01" @default.
• W4381432829 modified "2023-10-05" @default.
• W4381432829 title "Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial" @default.
• W4381432829 cites W3217661335 @default.
• W4381432829 cites W4200059599 @default.
• W4381432829 cites W4200505933 @default.
• W4381432829 cites W4205240144 @default.
• W4381432829 cites W4206675538 @default.
• W4381432829 cites W4206906464 @default.
• W4381432829 cites W4207047906 @default.
• W4381432829 cites W4210493562 @default.
• W4381432829 cites W4210704633 @default.
• W4381432829 cites W4213069125 @default.
• W4381432829 cites W4213143712 @default.
• W4381432829 cites W4220673385 @default.
• W4381432829 cites W4220830840 @default.
• W4381432829 cites W4221072241 @default.
• W4381432829 cites W4224950216 @default.
• W4381432829 cites W4225530712 @default.
• W4381432829 cites W4281571659 @default.
• W4381432829 cites W4281702570 @default.
• W4381432829 cites W4283326436 @default.
• W4381432829 cites W4285606826 @default.
• W4381432829 cites W4293843074 @default.
• W4381432829 cites W4302293777 @default.
• W4381432829 cites W4312067678 @default.
• W4381432829 doi "https://doi.org/10.1016/j.lanwpc.2023.100829" @default.
• W4381432829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37360864" @default.
• W4381432829 hasPublicationYear "2023" @default.
• W4381432829 type Work @default.
• W4381432829 citedByCount "0" @default.
• W4381432829 crossrefType "journal-article" @default.
• W4381432829 hasAuthorship W4381432829A5003217623 @default.
• W4381432829 hasAuthorship W4381432829A5010401056 @default.
• W4381432829 hasAuthorship W4381432829A5011028975 @default.
• W4381432829 hasAuthorship W4381432829A5017618823 @default.
• W4381432829 hasAuthorship W4381432829A5028939852 @default.
• W4381432829 hasAuthorship W4381432829A5030821637 @default.
• W4381432829 hasAuthorship W4381432829A5038863647 @default.
• W4381432829 hasAuthorship W4381432829A5040179741 @default.
• W4381432829 hasAuthorship W4381432829A5049507373 @default.
• W4381432829 hasAuthorship W4381432829A5057822709 @default.
• W4381432829 hasAuthorship W4381432829A5058131596 @default.
• W4381432829 hasAuthorship W4381432829A5060962650 @default.
• W4381432829 hasAuthorship W4381432829A5063228983 @default.
• W4381432829 hasAuthorship W4381432829A5063333893 @default.
• W4381432829 hasAuthorship W4381432829A5065172118 @default.
• W4381432829 hasAuthorship W4381432829A5070046055 @default.
• W4381432829 hasAuthorship W4381432829A5070493054 @default.
• W4381432829 hasAuthorship W4381432829A5072289684 @default.
• W4381432829 hasAuthorship W4381432829A5077191016 @default.
• W4381432829 hasAuthorship W4381432829A5077645027 @default.
• W4381432829 hasAuthorship W4381432829A5083040893 @default.
• W4381432829 hasAuthorship W4381432829A5089746659 @default.
• W4381432829 hasAuthorship W4381432829A5090384196 @default.
• W4381432829 hasBestOaLocation W43814328291 @default.
• W4381432829 hasConcept C104317684 @default.
• W4381432829 hasConcept C126322002 @default.
• W4381432829 hasConcept C159047783 @default.
• W4381432829 hasConcept C159654299 @default.
• W4381432829 hasConcept C168563851 @default.
• W4381432829 hasConcept C187212893 @default.
• W4381432829 hasConcept C197934379 @default.
• W4381432829 hasConcept C203014093 @default.
• W4381432829 hasConcept C22070199 @default.
• W4381432829 hasConcept C2777704310 @default.
• W4381432829 hasConcept C2780115692 @default.
• W4381432829 hasConcept C2780868878 @default.
• W4381432829 hasConcept C32611913 @default.
• W4381432829 hasConcept C55493867 @default.
• W4381432829 hasConcept C71924100 @default.
• W4381432829 hasConcept C86803240 @default.
• W4381432829 hasConceptScore W4381432829C104317684 @default.

• next